BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Xie DR, Liang HL, Wang Y, Guo SS, Yang Q. Meta-analysis on inoperable pancreatic cancer: A comparison between gemcitabine-based combination therapy and gemcitabine alone. World J Gastroenterol 2006; 12(43): 6973-6981 [PMID: 17109519 DOI: 10.3748/wjg.v12.i43.6973]
URL: https://www.wjgnet.com/1007-9327/full/v12/i43/6973.htm
Number Citing Articles
1
Manuel Hidalgo, Albert Abad, Enrique Aranda, Luis Díez, Jaime Feliu, Carlos Gómez, Antonio Irigoyen, Rafael López, Fernando Rivera, Carmen Rubio, Javier Sastre, Josep Tabernero, Eduardo Díaz-Rubio. Consensus on the treatment of pancreatic cancer in SpainClinical and Translational Oncology 2009; 11(5) doi: 10.1007/s12094-009-0357-3
2
JUN GONG, RICHARD TULI, ARVIND SHINDE, ANDREW E. HENDIFAR. Meta-analyses of treatment standards for pancreatic cancerMolecular and Clinical Oncology 2016; 4(3) doi: 10.3892/mco.2015.716
3
Axel Kleespies, Ivan Ischenko, Martin E. Eichhorn, Hendrik Seeliger, Christiane Amendt, Ole Mantell, Karl-Walter Jauch, Christiane J. Bruns. Matuzumab Short-Term Therapy in Experimental Pancreatic Cancer: Prolonged Antitumor Activity in Combination with GemcitabineClinical Cancer Research 2008; 14(17) doi: 10.1158/1078-0432.CCR-07-5245
4
A Sultana, C Tudur Smith, D Cunningham, N Starling, J P Neoptolemos, P Ghaneh. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analysesBritish Journal of Cancer 2008; 99(1) doi: 10.1038/sj.bjc.6604436
5
Kyung Hee Lee, Min Kyoung Kim, Yeol Hong Kim, Baek Yeol Ryoo, Ho Yeong Lim, Hong Suk Song, Hoon Kyo Kim, Myung Ah Lee, Seock Ah Im, Heung Moon Chang, Jae Yong Cho, Dae Young Zang, Bong Seog Kim, Jun Suk Kim. Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II studyCancer Chemotherapy and Pharmacology 2009; 64(2) doi: 10.1007/s00280-008-0873-9
6
Emilio Bria, Michele Milella, Alain Gelibter, Federica Cuppone, Maria Simona Pino, Enzo Maria Ruggeri, Paolo Carlini, Cecilia Nisticò, Edmondo Terzoli, Francesco Cognetti, Diana Giannarelli. Gemcitabine‐based combinations for inoperable pancreatic cancer: Have we made real progress?Cancer 2007; 110(3) doi: 10.1002/cncr.22809
7
Sareh Seyedi, Valerie K. Harris, Stefania E. Kapsetaki, Shrinath Narayanan, Daniel Saha, Zachary Compton, Rezvan Yousefi, Alexander May, Efe Fakir, Amy M. Boddy, Marco Gerlinger, Christina Wu, Lida Mina, Silvie Huijben, Dawn H. Gouge, Luis Cisneros, Peter C. Ellsworth, Carlo C. Maley. Resistance Management for Cancer: Lessons from FarmersCancer Research 2024; 84(22) doi: 10.1158/0008-5472.CAN-23-3374
8
H. Oettle, U. Pelzer, J. Stieler, H. Riess. Adjuvante und palliative Therapie des PankreaskarzinomsDer Onkologe 2010; 16(6) doi: 10.1007/s00761-010-1851-5
9
Christopher Paiji, V. Raman Muthusamy. Endoscopic Ultrasonography2024;  doi: 10.1002/9781119697893.ch24
10
D. r. Xie, Q. Yang, D. l. Chen, Z. m. Jiang, Z. f. Bi, W. Ma, Y. d. Zhang. Gemcitabine-based Cytotoxic Doublets Chemotherapy for Advanced Pancreatic Cancer: Updated Subgroup Meta-analyses of Overall SurvivalJapanese Journal of Clinical Oncology 2010; 40(5) doi: 10.1093/jjco/hyp198
11
Rei Suzuki, Atsushi Irisawa, Manoop S. Bhutani. Endoscopic Ultrasound-Guided Oncologic Therapy for Pancreatic CancerDiagnostic and Therapeutic Endoscopy 2013; 2013 doi: 10.1155/2013/157581
12
Kharat Aditi, Tan Chia Jie, Saeteaw Manit, Chhibber Anindit, Biskupiak Joseph, Veettil Sajesh K, Chaiyakunapruk Nathorn. Survival benefits and safety of chemotherapy regimens for pancreatic cancer: An umbrella review of meta-analyses of randomized controlled trialsAnnals of Pancreatic Disorders and Treatment 2022; 4(1) doi: 10.17352/apdt.000008
13
Min Xuan, Na Li, Chunyan Wu. A meta-analysis on the efficacy of endoscopic ultrasonography for treatment of pancreatic cancerClinics 2024; 79 doi: 10.1016/j.clinsp.2024.100348
14
Fenghua Liu, Yong Tang, Junwei Sun, Zhanna Yuan, Shasha Li, Jun Sheng, He Ren, Jihui Hao, James M. Wright. Regional Intra-Arterial vs. Systemic Chemotherapy for Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsPLoS ONE 2012; 7(7) doi: 10.1371/journal.pone.0040847
15
Ying-Jui Chao, Edgar D Sy, Hui-Ping Hsu, Yan-Shen Shan. Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapyBMC Surgery 2014; 14(1) doi: 10.1186/1471-2482-14-72
16
Hongxu Chen, Xiang Lan, Menggang Liu, Bo Zhou, Baoling Wang, Ping Chen. Direct TGF‐β1 signaling between activated platelets and pancreatic cancer cells primes cisplatin insensitivityCell Biology International 2013; 37(5) doi: 10.1002/cbin.10067
17
Amit Dang, Surendar Chidirala, Prashanth Veeranki, B.N. Vallish. A Critical Overview of Systematic Reviews of Chemotherapy for Advanced and Locally Advanced Pancreatic Cancer using both AMSTAR2 and ROBIS as Quality Assessment ToolsReviews on Recent Clinical Trials 2021; 16(2) doi: 10.2174/1574887115666200902111510
18
George Fountzilas, Mattheos Bobos, Anna Kalogera-Fountzila, Nikolaos Xiros, Samuel Murray, Helena Linardou, Georgia Karayannopoulou, Angelos K. Koutras, Dimitrios Bafaloukos, Epaminondas Samantas, Christos Christodoulou, Theofanis Economopoulos, Konstantine T. Kalogeras, Paris Kosmidis. Gemcitabine Combined with Gefitinib in Patients with Inoperable or Metastatic Pancreatic Cancer: A Phase II Study of the Hellenic Cooperative Oncology Group with Biomarker EvaluationCancer Investigation 2008; 26(8) doi: 10.1080/07357900801918611
19
Guoqing Ouyang, Zhipeng Liu, Shengfu Huang, Qianglong Li, Li Xiong, Xiongying Miao, Yu Wen. Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysisWorld Journal of Surgical Oncology 2016; 14(1) doi: 10.1186/s12957-016-0813-9
20
Emmanuel Mitry, Pascal Hammel, Gaël Deplanque, Françoise Mornex, Philippe Levy, Jean-François Seitz, Alain Moussy, Jean-Pierre Kinet, Olivier Hermine, Philippe Rougier, Eric Raymond. Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancerCancer Chemotherapy and Pharmacology 2010; 66(2) doi: 10.1007/s00280-010-1299-8
21
Carlos Gómez-Martín, Manuel Hidalgo, Josep Tabernero, Dolores Isla. SEOM clinical guidelines for the treatment of pancreatic cancerClinical and Translational Oncology 2011; 13(8) doi: 10.1007/s12094-011-0693-y
22
Wang Zhongmin, Liu Yu, Liu Fenju, Chen Kemin, Huang Gang. Clinical efficacy of CT-guided iodine-125 seed implantation therapy in patients with advanced pancreatic cancerEuropean Radiology 2010; 20(7) doi: 10.1007/s00330-009-1703-0
23
Zhendong Jin, Kenneth J. Chang. Endoscopic Ultrasound-Guided Fiducial Markers and BrachytherapyGastrointestinal Endoscopy Clinics of North America 2012; 22(2) doi: 10.1016/j.giec.2012.04.012
24
A. Maraveyas, J. Waters, R. Roy, D. Fyfe, D. Propper, F. Lofts, J. Sgouros, E. Gardiner, K. Wedgwood, C. Ettelaie, G. Bozas. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancerEuropean Journal of Cancer 2012; 48(9) doi: 10.1016/j.ejca.2011.10.017
25
Kourosh F. Ghassemi, V. Raman Muthusamy. Endoscopic Ultrasonography2016;  doi: 10.1002/9781118781067.ch25
26
Jae-Hyuk Choi, Sung Yong Oh, Hyuk-Chan Kwon, Jung Hwan Kim, Jae Hoon Lee, Suee Lee, Dong Mee Lee, Sung-Hyun Kim, Myung Hwan Rho, Young-Hoon Kim, Mee-Sook Rho, Hyo-Jin Kim. Gemcitabine versus Gemcitabine Combined with Cisplatin Treatment Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective AnalysisCancer Research and Treatment 2008; 40(1) doi: 10.4143/crt.2008.40.1.22
27
Surbhi Chouhan, Anil Kumar, Naoshad Muhammad, Darksha Usmani, Tabish H. Khan. Sirtuins as Key Regulators in Pancreatic Cancer: Insights into Signaling Mechanisms and Therapeutic ImplicationsCancers 2024; 16(23) doi: 10.3390/cancers16234095
28
Fernando Rivera, Sara López-Tarruella, Ma Eugenia Vega-Villegas, Matilde Salcedo. Treatment of advanced pancreatic cancer: From gemcitabine single agent to combinations and targeted therapyCancer Treatment Reviews 2009; 35(4) doi: 10.1016/j.ctrv.2008.11.007
29
Eileen M. O’Reilly, Ghassan K. Abou-Alfa. Cytotoxic Therapy for Advanced Pancreatic AdenocarcinomaSeminars in Oncology 2007; 34(4) doi: 10.1053/j.seminoncol.2007.05.009
30
Volker Heinemann, Stefan Boeck, Axel Hinke, Roberto Labianca, Christophe Louvet. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancerBMC Cancer 2008; 8(1) doi: 10.1186/1471-2407-8-82
31
Sridhar P. Susheela, Swaroop Revannasiddaiah, Ajaikumar Basavalingaiah. Stereotactic Hypofractionated Irradiation for Metastatic, Inoperable, and Recurrent Malignancies: A Modern Necessity, rather than a LuxuryJournal of Radiotherapy 2014; 2014 doi: 10.1155/2014/489824
32
Qin Li, Han Yan, Wenting Liu, Hongchao Zhen, Yifan Yang, Bangwei Cao, Jonathan R. Brody. Efficacy and Safety of Gemcitabine-Fluorouracil Combination Therapy in the Management of Advanced Pancreatic Cancer: A Meta-Analysis of Randomized Controlled TrialsPLoS ONE 2014; 9(8) doi: 10.1371/journal.pone.0104346